Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Key Laboratory of Druggability of Biopharmaceutics, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Pharm Res. 2018 Feb 27;35(4):77. doi: 10.1007/s11095-018-2370-0.
A multidrug resistance (MDR) modulator, disulfiram (DSF), was incorporated into pure paclitaxel (PTX) nanoparticles to construct a smart paclitaxel-disulfiram nanococrystals (PTX-DSF Ns) stabilized by β-lactoglobulin (β-LG), with the aim to reverse MDR and therefore enhnce cytotoxicity towards Taxol-resistant A549 cells (A549/TAX).
PTX-DSF Ns was prepared by antisolvent precipitation method. Flow cytometry was used to determine the cell uptake, drug efflux inhibition, cell cycle phase arrest and apoptosis. MDR-1 gene expression level was detected by real time quantitative PCR and gel electrophoresis.
PTX-DSF Ns prepared from the optimized formulation had an optimum diameter of 160 nm, was stable and had a high drug-loading capacity. Importantly, the uptake of PTX-DSF Ns in A549/TAX cells was 14-fold greater than the uptake of PTX Ns. Furthermore, PTX-DSF Ns promoted 5-folds increase in apoptosis, enabled 7-folds reduction in the IC, and rendered 8.9-fold decrease in the dose compared with free PTX.
PTX-DSF Ns with a precise mass ratio offer efficient cytotoxicity against Taxol-resistant cells and a novel approach for codelivery and sensitizing MDR cancer to chemotherapy. In addition, the use of nanosuspensions as a combined treatment provides a new research avenue for nanosuspensions.
将多药耐药(MDR)调节剂双硫仑(DSF)掺入纯紫杉醇(PTX)纳米颗粒中,构建由β-乳球蛋白(β-LG)稳定的智能紫杉醇-双硫仑纳米共晶体(PTX-DSF Ns),旨在逆转 MDR 并因此增强对紫杉醇耐药 A549 细胞(A549/TAX)的细胞毒性。
采用反溶剂沉淀法制备 PTX-DSF Ns。采用流式细胞术测定细胞摄取、药物外排抑制、细胞周期阻滞和细胞凋亡。采用实时定量 PCR 和凝胶电泳检测 MDR-1 基因表达水平。
从优化的配方中制备的 PTX-DSF Ns 的最佳粒径为 160nm,具有稳定性和高载药量。重要的是,PTX-DSF Ns 在 A549/TAX 细胞中的摄取量是 PTX Ns 的 14 倍。此外,PTX-DSF Ns 促进细胞凋亡增加 5 倍,使 IC 降低 7 倍,与游离 PTX 相比,剂量降低 8.9 倍。
具有精确质量比的 PTX-DSF Ns 对紫杉醇耐药细胞具有高效的细胞毒性,并为联合递药和增敏 MDR 癌症化疗提供了新的方法。此外,纳米混悬剂作为联合治疗的应用为纳米混悬剂的研究提供了新的途径。